| Literature DB >> 28752224 |
Miren Ettcheto1,2,3,4, Sonia Abad1,3, Dmitry Petrov1,3, Ignacio Pedrós2,3, Oriol Busquets1,2,3,4, Elena Sánchez-López5,6, Gemma Casadesús7, Carlos Beas-Zarate8, Eva Carro3,9, Carme Auladell3,4,10, Jordi Olloquequi11, Merce Pallàs1,3,4, Jaume Folch2,3, Antoni Camins12,13,14,15.
Abstract
The molecular basis of memory loss in Alzheimer's disease (AD), the main cause of senile dementia, is under investigation. In the present study, we have focused on the early hippocampal memory-related changes in APPswe/PS1dE9 (APP/PS1) mice, a well-established mouse model of familial AD. It is well known that molecules like cAMP response element binding (CREB) and binding protein (CBP) play a crucial role in memory consolidation. We analyzed CBP on its transcriptional activity and protein levels, finding a significant downregulation of both of them at 3-month-old mice. In addition, the downregulation of this molecule was associated with a decrease on acetylation levels of histone H3 in the hippocampus of APP/PS1 mice. Moreover, the p-CREB levels, which are important for memory acquisition at 3 months in APP/PS1 mice, were downregulated. Furthermore, we suggest that early neuroinflammation, especially due to the Tnfα gene increased expression, could also be responsible to this process of memory loss. Given all the previously mentioned results, we propose that an early suitable treatment to prevent the evolution of the disease should include a combination of drugs, including anti-inflammatories, which may decrease glial activation and Tnfα levels, and phosphodiesterase inhibitors that increase cAMP levels.Entities:
Keywords: APPSwe/PS1dE9; Alzheimer disease; CBP; CREB; Hippocampus
Mesh:
Substances:
Year: 2017 PMID: 28752224 DOI: 10.1007/s12035-017-0690-4
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590